New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 14, 2014
16:02 EDTNEONeoGenomics files to sell common stock, no amount given
NeoGenomics anticipates using the net proceeds from the offering for working capital, capital expenditures and other corporate purposes, including potential acquisitions and the repayment of debt. William Blair & Company, L.L.C. is the sole book-running manager and Craig-Hallum Capital Group LLC is co-lead manager for the offering. Stephens Inc., Roth Capital Partners, LLC, Sidoti & Company, LLC and Dawson James Securities, Inc. are serving as co-managers for the offering.
News For NEO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 25, 2015
08:40 EDTNEONeoGenomics reimbursement rates could rebound, says Roth Capital
Roth Capital expects reimbursement rates for NeoGenomics' tests to rebound in 2H15, since the firm believes, based on data, that most labs are probably performing the tests below costs. The firm keeps a $7 price target and Buy rating on NeoGenomics.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use